Harpoon Therapeutics Past Earnings Performance
Past criteria checks 0/6
Harpoon Therapeutics's earnings have been declining at an average annual rate of -10.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 41.4% per year.
Key information
-10.2%
Earnings growth rate
53.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 41.4% |
| Return on equity | -671.6% |
| Net Margin | -81.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Harpoon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 37 | -30 | 16 | 0 |
| 30 Jun 23 | 47 | -40 | 16 | 0 |
| 31 Mar 23 | 35 | -59 | 18 | 0 |
| 31 Dec 22 | 32 | -68 | 19 | 0 |
| 30 Sep 22 | 32 | -71 | 20 | 0 |
| 30 Jun 22 | 23 | -76 | 20 | 0 |
| 31 Mar 22 | 21 | -75 | 19 | 0 |
| 31 Dec 21 | 24 | -117 | 18 | 0 |
| 30 Sep 21 | 27 | -107 | 17 | 0 |
| 30 Jun 21 | 26 | -103 | 17 | 0 |
| 31 Mar 21 | 23 | -99 | 17 | 0 |
| 31 Dec 20 | 17 | -50 | 16 | 0 |
| 30 Sep 20 | 12 | -53 | 17 | 0 |
| 30 Jun 20 | 10 | -55 | 21 | 0 |
| 31 Mar 20 | 8 | -55 | 20 | 0 |
| 31 Dec 19 | 6 | -56 | 22 | 0 |
| 30 Sep 19 | 5 | -51 | 20 | 0 |
| 30 Jun 19 | 4 | -42 | 14 | 0 |
| 31 Mar 19 | 4 | -36 | 11 | 0 |
| 31 Dec 18 | 5 | -27 | 6 | 0 |
| 30 Sep 18 | 4 | -23 | 5 | 0 |
| 31 Dec 17 | 1 | -17 | 4 | 0 |
Quality Earnings: 5HTA is currently unprofitable.
Growing Profit Margin: 5HTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5HTA is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare 5HTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5HTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).
Return on Equity
High ROE: 5HTA has a negative Return on Equity (-671.61%), as it is currently unprofitable.